VRDN
Viridian Therapeutics, Inc.
1W: -5.9%
1M: -4.0%
3M: -16.0%
YTD: -12.1%
1Y: +74.8%
3Y: -5.2%
5Y: +44.7%
$26.98
-0.86 (-3.09%)
After Hours: $29.41 (+2.43, +9.03%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$41.9M
Congress—
ETF Holdings—
Key Statistics
Market Cap$2.3B
52W Range9.9-34.29
Volume3,324,032
Avg Volume1,345,476
Beta1.01
Dividend—
Analyst Ratings
Company Info
CEOStephen F. Mahoney
Employees143
SectorHealthcare
IndustryBiotechnology
IPO Date2014-06-18
Websiteviridiantherapeutics.com
221 Crescent Street
Waltham, MA 02453
US
Waltham, MA 02453
US
617 272 4600
About Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
Latest News
This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know
What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down
VR Adviser Adds Over 1 Million Savara Shares
Viridian Therapeutics misses Q4 estimates
Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Misses Revenue Estimates
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Tousignant Jennifer | F-InKind | 1,675 | $30.19 | 2026-03-03 |
| Mahoney Stephen F. | F-InKind | 7,408 | $30.19 | 2026-03-03 |
| Harmon Seth | F-InKind | 2,031 | $30.19 | 2026-03-03 |
| Beetham Thomas W. | F-InKind | 3,048 | $30.19 | 2026-03-03 |
| Beetham Thomas W. | M-Exempt | 9,409 | — | 2026-03-03 |